Aileron Therapeutics to Present at the 8th Annual IPF Summit
Aileron Therapeutics to Present at the 8th Annual IPF Summit
The IPF Summit is the largest drug development initiative for the pulmonary fibrosis community, bringing together key biopharmaceutical companies, clinicians, and academic researchers from around the globe. For more information about the IPF Summit, please visit ipf-summit.com.AUSTIN, Texas, Aug. 19, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer of Aileron, will present at the 8th Annual IPF Summit taking place August 20-22, 2024 in Boston, MA.
2024年8月19日，德克萨斯州奥斯汀/美通社/--生物医药公司艾勒隆治疗公司（"艾勒隆"）（纳斯达克:ALRN）推进一系列创新药物管线，以解决特殊小众肺部和纤维化相关问题的重大未满足医疗需求。今天宣布，艾勒隆公司总裁兼首席执行官Brian Windsor博士将出席于2024年8月20日至22日在马萨诸塞州波士顿举行的第八届IPF峰会，并发表演讲。
Details of the presentation are as follows:
演示的详细信息如下:
Presentation Title: Biomarker Strategies in the Clinical Development of LTI-03 in IPF
Session: Emerging Biology & Early Translation | Uncovering a Translational Framework of Preclinical Modelling to Enhance the Predictive Power & Navigate from Bench to Bedside for the Next-Gen Therapeutics
Date & Time: Wednesday, August 21, 2024, at 2:45 PM ET
演讲题目:基于生物标志物的LTI-03在IPF临床开发中的策略
版块:新兴生物学与早期转化|揭示基于临床前模型的转化框架，增强预测力并导航从实验室到床边的下一代治疗法
日期和时间：2024年8月21日周三下午2:45 美国东部时间
The IPF Summit is the largest drug development initiative for the pulmonary fibrosis community, bringing together key biopharmaceutical companies, clinicians, and academic researchers from around the globe. For more information about the IPF Summit, please visit ipf-summit.com.
IPF峰会是针对肺纤维化社区的最大药物开发举措，汇集了来自全球的关键生物医药公司、临床医师和学术研究人员。有关IPF峰会的更多信息，请访问ipf-summit.com。
About Aileron Therapeutics
关于Aileron Therapeutics
Aileron Therapeutics is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Currently, LTI-03 is being evaluated in a Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis, with Cohort 2 results expected to be reported in the third quarter this year. Aileron's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US.
Aileron Therapeutics是一家生物制药公司，致力于开发一系列新药管线，以解决孤儿肺和纤维化疾病领域的重大医疗需求。Aileron的主打产品候选药物LTI-03是一种新型的合成肽，具有双重机制，旨在促进肺泡上皮细胞的存活，同时抑制纤维化信号的传递。目前，LTI-03正在进行第1b期临床试验，用于治疗特发性肺纤维化，预计第2组结果将于今年第三季度公布。Aileron的第二个产品候选药物LTI-01是一种前酶，已完成用于治疗局限性胸膜积液的第1b期和第2a期临床试验，在美国和欧盟获得了孤儿药物认证和美国快速通道认证。
Investor Relations & Media Contact:
Argot Partners
[email protected]
212-600-1902
投资者关系和媒体联系人：
阿哥特合伙人。
[email protected]
212-600-1902
SOURCE Aileron Therapeutics, Inc.
Aileron Therapeutics, Inc的消息来源。
